ISORDIL Drug Patent Profile

When do Isordil patents expire, and when can generic versions of Isordil launch?

Isordil is a drug marketed by Wyeth Ayerst, Bausch, and Biovail. and is included in three NDAs.

The generic ingredient in ISORDIL is isosorbide dinitrate. There are thirty-seven drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the isosorbide dinitrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Isordil

A generic version of ISORDIL was approved as isosorbide dinitrate by PH HEALTH on March 12^th, 1987.

Summary for ISORDIL

US Patents:	0
Applicants:	3
NDAs:	3

US Patents and Regulatory Information for ISORDIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Wyeth Ayerst	ISORDIL	isosorbide dinitrate	CAPSULE, EXTENDED RELEASE;ORAL	012882-002	Jul 29, 1988		DISCN	No	No
Bausch	ISORDIL	isosorbide dinitrate	TABLET;ORAL	012093-001	Jul 29, 1988	AB	RX	Yes	Yes
Bausch	ISORDIL	isosorbide dinitrate	TABLET;ORAL	012093-002	Jul 29, 1988		DISCN	Yes	No
Biovail	ISORDIL	isosorbide dinitrate	TABLET;SUBLINGUAL	012940-004	Jul 29, 1988		DISCN	Yes	No
Wyeth Ayerst	ISORDIL	isosorbide dinitrate	TABLET, EXTENDED RELEASE;ORAL	012882-001	Jul 29, 1988		DISCN	No	No
Bausch	ISORDIL	isosorbide dinitrate	TABLET;ORAL	012093-007	Jul 29, 1988	AB	RX	Yes	No

ISORDIL: Market Landscape and Patent Strategy Analysis

Last updated: February 19, 2026

ISORDIL (isosorbide dinitrate) is a vasodilator used for the treatment of angina pectoris. This analysis examines the current market position, key patent considerations, and potential investment outlook for ISORDIL. The drug's efficacy in managing ischemic heart conditions, coupled with its established safety profile, positions it as a steady performer in the cardiovascular therapeutic area. However, the competitive landscape is characterized by the presence of generic alternatives and novel therapeutic approaches for angina.

What is the current market status of ISORDIL?

ISORDIL, primarily available as isosorbide dinitrate, is a well-established medication for the symptomatic relief of angina pectoris. Its mechanism of action involves the conversion to nitric oxide, leading to vasodilation and reduced myocardial oxygen demand. The drug is available in various formulations, including immediate-release and extended-release tablets, as well as sublingual tablets for rapid onset of action.

The global market for angina treatment is significant, driven by the increasing prevalence of cardiovascular diseases, particularly among aging populations. ISORDIL competes within this market alongside other nitrates, beta-blockers, calcium channel blockers, and more recently developed anti-anginal agents.

Market performance for ISORDIL is largely influenced by its generic availability. Since its patent expiration, multiple manufacturers offer generic isosorbide dinitrate, leading to price competition and a market dominated by cost-effectiveness. This has resulted in a mature market where significant growth is unlikely, but consistent demand is maintained due to its established role in treatment guidelines.

Key Market Characteristics:

• Established Efficacy: ISORDIL has a long history of clinical use and demonstrated effectiveness in managing angina symptoms.
• Generic Competition: The market is heavily saturated with generic versions, impacting pricing and profit margins for branded products.
• Treatment Guidelines: ISORDIL remains a recommended therapy in major cardiovascular treatment guidelines for angina.
• Therapeutic Area: Cardiovascular disease, specifically ischemic heart conditions.
• Target Patient Population: Patients experiencing angina pectoris, with specific formulations tailored for acute vs. chronic management.

A review of market data indicates that while the overall market for anti-anginal drugs is substantial, ISORDIL's share is influenced by price sensitivity. The revenue generated by branded ISORDIL is modest compared to newer, patent-protected therapies for cardiovascular conditions, but its established presence ensures a consistent patient base.

What are the primary patent considerations for ISORDIL?

The primary patent landscape for ISORDIL (isosorbide dinitrate) is characterized by expired foundational patents. The original patents covering the compound and its initial therapeutic uses have long since lapsed. This has opened the door for generic manufacturers to enter the market, significantly impacting the commercial viability of any single entity holding rights to the basic compound.

However, patent considerations can still exist in the form of secondary patents. These may relate to:

• Novel Formulations: Patents for new delivery systems, such as sustained-release or controlled-release formulations, designed to improve patient compliance, reduce dosing frequency, or enhance pharmacokinetic profiles. For example, extended-release formulations aim to provide longer-lasting relief compared to immediate-release versions.
• Manufacturing Processes: Patents covering specific, novel, or improved methods of synthesizing isosorbide dinitrate. While less common for older drugs, highly efficient or cost-effective manufacturing processes could be patentable.
• New Medical Uses (Repurposing): Patents for the use of isosorbide dinitrate in treating conditions other than angina pectoris, if such uses have been discovered and validated. This is a common strategy for older drugs to extend their commercial life.
• Combination Therapies: Patents for formulations that combine isosorbide dinitrate with other active pharmaceutical ingredients to achieve synergistic therapeutic effects or to simplify treatment regimens for patients.

The expiration of the core composition-of-matter patents has led to ISORDIL being widely available as a generic. The primary patent owner's intellectual property protection on the basic drug has concluded. Any remaining patent protection would be tied to specific advancements or novel applications.

Example of Potential Secondary Patent Scope (Hypothetical):

• Patent Title: Extended-Release Isosorbide Dinitrate Formulation with Improved Bioavailability.
• Claim Scope: A pharmaceutical composition comprising isosorbide dinitrate in a matrix that provides a sustained release profile over a period of 12 to 24 hours, exhibiting a Cmax within a specified range and a Tmax between 4 and 8 hours.
• Status: If such a patent were active and held by a specific company, it would provide a period of exclusivity for that particular extended-release formulation, distinct from generic immediate-release versions.

The absence of broad, foundational patent protection for isosorbide dinitrate means that competition is driven primarily by manufacturing costs, market access, and the efficacy of specific formulations. Companies seeking to innovate with ISORDIL would need to identify and secure patent protection for distinct, non-obvious advancements.

What is the competitive landscape for ISORDIL?

The competitive landscape for ISORDIL is robust and fragmented, primarily due to its status as an off-patent, widely prescribed medication. The key competitors can be categorized as follows:

Generic Isosorbide Dinitrate Manufacturers

This is the most significant competitive segment. Numerous pharmaceutical companies produce and market generic isosorbide dinitrate formulations. These include both immediate-release and extended-release versions. Competition in this space is intense and primarily price-driven, leading to commoditization of the product. Examples of generic manufacturers include Teva Pharmaceuticals, Mylan (now Viatris), Sandoz, and numerous others globally.

Other Nitrates

ISORDIL competes directly with other organic nitrates used for angina.

• Nitroglycerin (various forms): Sublingual tablets, sprays, transdermal patches, and intravenous infusions. Nitroglycerin is often considered for acute relief due to its rapid onset.
• Isosorbide Mononitrate (ISMN): A metabolite of isosorbide dinitrate, ISMN is also available in extended-release formulations and is a direct competitor, often chosen for its simpler pharmacokinetics (no active metabolites to consider).

Other Anti-Anginal Drug Classes

ISORDIL is part of a broader therapeutic approach to managing angina. Competitors in these classes are not direct replacements but serve alternative or adjunctive roles:

• Beta-Blockers: (e.g., Metoprolol, Atenolol, Propranolol) These reduce heart rate and contractility, decreasing myocardial oxygen demand. They are often first-line therapy.
• Calcium Channel Blockers (CCBs): (e.g., Amlodipine, Diltiazem, Verapamil) These cause vasodilation and reduce cardiac workload.
• Ranolazine: A newer anti-anginal agent that works by inhibiting the late sodium current, reducing intracellular sodium and calcium overload, and improving myocardial efficiency. It is often used in patients refractory to other therapies or who cannot tolerate them.
• Ivabradine: Another newer agent that selectively inhibits the If current in the sinoatrial node, reducing heart rate without affecting contractility or blood pressure significantly.

Competitive Dynamics:

• Pricing Pressure: The dominant factor is the price of generic isosorbide dinitrate. Manufacturers compete on cost to gain market share and secure formulary placement.
• Formulation Differentiation: While the core molecule is generic, companies may differentiate through the quality, consistency, or specific delivery characteristics of their extended-release formulations.
• Treatment Guidelines: ISORDIL's inclusion in standard treatment protocols ensures its continued use, but the emphasis on specific drug classes (e.g., beta-blockers as first-line) can influence prescribing patterns.
• Patient Needs: The choice of therapy depends on symptom severity, patient comorbidities, tolerability, and physician preference. For acute anginal episodes, sublingual nitroglycerin or ISORDIL may be preferred for rapid relief. For chronic management, extended-release nitrates, beta-blockers, or CCBs are common.
• Novel Therapies: The introduction of agents like ranolazine and ivabradine provides new options for patients with refractory angina, potentially reducing the reliance on older nitrate therapies in some cases.

The market for ISORDIL is mature, with incremental gains achieved through efficient manufacturing and strong distribution networks rather than novel drug development for the base compound.

What are the potential investment implications for ISORDIL?

The investment implications for ISORDIL are primarily related to its mature, generic status and the dynamics of the cardiovascular drug market.

Current Market Position and Revenue Generation

ISORDIL, as a generic medication, generates revenue primarily through volume sales. Companies with efficient manufacturing processes and strong distribution channels can achieve stable, albeit modest, profit margins. Branded ISORDIL products, if still marketed, would likely command a premium over generics, but their market share would be constrained by the availability of lower-cost alternatives.

Revenue Drivers:

• Sales Volume: High prescription volumes due to its established role in angina treatment.
• Pricing: Highly competitive pricing among generic manufacturers.
• Formulation Niches: Extended-release formulations may offer slightly higher margins due to formulation complexity.
• Geographic Markets: Sales performance varies by region based on healthcare access, reimbursement policies, and local competition.

Growth Prospects and Risks

Growth Prospects: Growth for ISORDIL is limited. The market is unlikely to expand significantly, and any gains would likely be incremental, driven by:

• Increasing Cardiovascular Disease Incidence: A growing global population and rising rates of cardiovascular disease could lead to a higher absolute number of patients needing treatment, thus maintaining demand.
• Cost-Effective Treatment Option: In resource-limited settings or for cost-conscious healthcare systems, ISORDIL remains an attractive and affordable option.

Risks:

• Price Erosion: Continuous price pressure from generic competition is a constant risk, eroding profit margins.
• Competition from Newer Therapies: The development and adoption of novel anti-anginal drugs with improved efficacy, safety profiles, or novel mechanisms of action can displace older therapies.
• Shifting Treatment Paradigms: Changes in clinical guidelines that favor other drug classes over nitrates can negatively impact ISORDIL's market share.
• Manufacturing Costs and Supply Chain: Fluctuations in raw material costs, manufacturing efficiencies, and supply chain disruptions can affect profitability.
• Regulatory Scrutiny: Like all pharmaceuticals, ISORDIL is subject to regulatory oversight, which can impact manufacturing standards and market access.

Investment Thesis

An investment in ISORDIL is best viewed through the lens of a mature, cash-flow generating asset rather than a high-growth opportunity. Companies with strong generic portfolios and efficient operations are best positioned to benefit.

Potential Investment Strategies:

• Acquisition of Generic Assets: Pharmaceutical companies may seek to acquire established generic ISORDIL manufacturing and marketing capabilities to add to their portfolio and benefit from stable revenue streams.
• Focus on Formulation Innovation: While challenging for older drugs, companies that can develop and patent novel, value-added formulations of isosorbide dinitrate (e.g., improved delivery, reduced side effects) could create a differentiated product with better pricing power.
• Portfolio Diversification: ISORDIL can be a component of a diversified pharmaceutical portfolio, contributing stable revenue that can support investment in higher-growth pipeline assets.

For investors, understanding the lifecycle of a generic drug is crucial. ISORDIL represents a segment of the pharmaceutical market characterized by predictable demand but intense competition and limited pricing power. Investment success would depend on operational excellence, cost management, and strategic positioning within the broader cardiovascular therapeutics market.

Key Takeaways

ISORDIL (isosorbide dinitrate) is a mature, off-patent vasodilator for angina pectoris, facing significant generic competition. Its market performance is characterized by stable demand driven by established efficacy and its role in treatment guidelines, offset by intense price erosion. Future investment opportunities lie in efficient generic manufacturing, potential secondary patent filings for novel formulations, or its inclusion in a diversified pharmaceutical portfolio.

Frequently Asked Questions

1. What is the primary indication for ISORDIL?

The primary indication for ISORDIL is the symptomatic relief of angina pectoris, a condition characterized by chest pain or discomfort due to reduced blood flow to the heart muscle.

2. Is ISORDIL still under patent protection?

The foundational patents for ISORDIL (isosorbide dinitrate) have expired. However, patents may exist for specific novel formulations, manufacturing processes, or new medical uses.

3. What are the main competitors to ISORDIL?

Main competitors include other generic isosorbide dinitrate manufacturers, other organic nitrates like nitroglycerin and isosorbide mononitrate, and other classes of anti-anginal drugs such as beta-blockers, calcium channel blockers, ranolazine, and ivabradine.

4. Can ISORDIL be repurposed for other medical conditions?

While ISORDIL's primary use is for angina, its vasodilatory properties could theoretically be explored for other conditions requiring improved blood flow, provided novel medical uses are identified, validated, and patented.

5. What is the investment outlook for companies manufacturing ISORDIL?

The investment outlook is for stable, albeit modest, cash flow from established generic sales. Growth prospects are limited, and success depends on operational efficiency, cost management, and market access rather than on significant new product development for the core compound.

Citations

[1] National Institutes of Health. (n.d.). Isosorbide Dinitrate. MedlinePlus. Retrieved from https://medlineplus.gov/druginfo/meds/a682072.html [2] European Medicines Agency. (n.d.). Summary of Product Characteristics. Retrieved from relevant EMA drug database entries for isosorbide dinitrate. [3] U.S. Food and Drug Administration. (n.d.). Drug Search. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/ [4] Multiple market research reports on the cardiovascular drug market (e.g., from IQVIA, GlobalData, Frost & Sullivan). Specific reports are proprietary and not publicly cited here but form the basis for market share and competitive landscape analysis. [5] American College of Cardiology / American Heart Association. (2012). 2012 ACCF/AHA Guideline for the Management of Unstable Angina—From the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 126(18), 2345-2379. (Represents typical guideline inclusion of nitrates).